ATE393152T1 - Phtalazine derivate mit angiogenesis inhibierender wirkung - Google Patents

Phtalazine derivate mit angiogenesis inhibierender wirkung

Info

Publication number
ATE393152T1
ATE393152T1 AT02738031T AT02738031T ATE393152T1 AT E393152 T1 ATE393152 T1 AT E393152T1 AT 02738031 T AT02738031 T AT 02738031T AT 02738031 T AT02738031 T AT 02738031T AT E393152 T1 ATE393152 T1 AT E393152T1
Authority
AT
Austria
Prior art keywords
treatment
derivatives
phtalazine
inhibiting effect
angiogenesis inhibiting
Prior art date
Application number
AT02738031T
Other languages
English (en)
Inventor
Guido Bold
Paul Manley
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE393152T1 publication Critical patent/ATE393152T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02738031T 2001-05-04 2002-05-03 Phtalazine derivate mit angiogenesis inhibierender wirkung ATE393152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111078.2A GB0111078D0 (en) 2001-05-04 2001-05-04 Organic compounds

Publications (1)

Publication Number Publication Date
ATE393152T1 true ATE393152T1 (de) 2008-05-15

Family

ID=9914117

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738031T ATE393152T1 (de) 2001-05-04 2002-05-03 Phtalazine derivate mit angiogenesis inhibierender wirkung

Country Status (12)

Country Link
US (3) US7399761B2 (de)
EP (1) EP1387836B1 (de)
JP (1) JP4365586B2 (de)
CN (1) CN1314681C (de)
AT (1) ATE393152T1 (de)
BR (1) BR0209332A (de)
CA (1) CA2446051A1 (de)
DE (1) DE60226225T2 (de)
ES (1) ES2301648T3 (de)
GB (1) GB0111078D0 (de)
PT (1) PT1387836E (de)
WO (1) WO2002090346A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1427420T1 (sl) * 2001-09-12 2006-12-31 Novartis Ag Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka
CA2490130A1 (en) 2002-06-28 2004-01-08 Novartis Ag Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor
AU2003292888A1 (en) * 2002-12-27 2004-07-22 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US7786130B2 (en) * 2005-08-29 2010-08-31 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
US8350026B2 (en) 2008-08-27 2013-01-08 Leo Pharma A/S VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
US9458105B2 (en) * 2012-11-16 2016-10-04 Hoffmann-La Roche Inc. Inhibitors of Bruton's tyrosine kinase
CN108299400B (zh) 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (de) 1957-05-07
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
JPH03106875A (ja) 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
HU219864B (hu) 1994-08-09 2001-08-28 Eisai Co., Ltd. cGMP-PDE inhibitor kondenzált piridazinszármazékok és alkalmazásuk
DE69705819T2 (de) 1996-01-15 2002-04-11 Janssen Pharmaceutica N.V., Beerse Angiogenesis hemmende pyridazinamine
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
BR0009507A (pt) * 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis

Also Published As

Publication number Publication date
BR0209332A (pt) 2004-07-20
US20040180899A1 (en) 2004-09-16
ES2301648T3 (es) 2008-07-01
CA2446051A1 (en) 2002-11-14
EP1387836B1 (de) 2008-04-23
JP4365586B2 (ja) 2009-11-18
WO2002090346A1 (en) 2002-11-14
US8034814B2 (en) 2011-10-11
CN1507444A (zh) 2004-06-23
JP2004532241A (ja) 2004-10-21
DE60226225D1 (de) 2008-06-05
DE60226225T2 (de) 2009-09-10
GB0111078D0 (en) 2001-06-27
PT1387836E (pt) 2008-06-27
US20110130399A1 (en) 2011-06-02
EP1387836A1 (de) 2004-02-11
US20090076003A1 (en) 2009-03-19
US7399761B2 (en) 2008-07-15
CN1314681C (zh) 2007-05-09

Similar Documents

Publication Publication Date Title
RU93004484A (ru) Производные пиразола, способ их получения и содержащие их фармацевтические композиции
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EP1592665A4 (de) Neue benzamidderivate als histondeacetylaseinhibitoren mit wirksamer differenzierung und antiproliferationswirkung
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BR0009507A (pt) Derivados de ftalazina para o tratamento de doenças inflamatórias
TR199900674T2 (xx) Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler.
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE393152T1 (de) Phtalazine derivate mit angiogenesis inhibierender wirkung
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE0002729D0 (sv) Novel compound form
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1387836

Country of ref document: EP